A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

AIMS: Risdiplam (RG7916, RO7034067) is an orally administered, centrally and peripherally distributed, survival of motor neuron 2 (SMN2) mRNA splicing modifier for the treatment of spinal muscular atrophy (SMA). The objectives of this entry‐into‐human study were to assess the safety, tolerability, p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Sturm, Stefan, Günther, Andreas, Jaber, Birgit, Jordan, Paul, Al Kotbi, Nada, Parkar, Nikhat, Cleary, Yumi, Frances, Nicolas, Bergauer, Tobias, Heinig, Katja, Kletzl, Heidemarie, Marquet, Anne, Ratni, Hasane, Poirier, Agnès, Müller, Lutz, Czech, Christian, Khwaja, Omar
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6303280/
https://ncbi.nlm.nih.gov/pubmed/30302786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13786
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars